Practice 9

Question 1

Which of the following safety monitoring parameters of niacin therapy? SATA

1. LFTs
2. Serum potassium
3. Serum uric acid level
4. Serum sodium

Answer 1

LFTs

Serum uric acid level

Question 2

Which of the following are SAFETY monitoring parameters of digoxin therapy? SATA

1. Serum uric acid level
2. Heart rhythm
3. Serum potassium
4. Serum sodium

Answer 2

Heart rhythm

Serum potassium

Question 3

Which of the following are safety monitoring parameters of amiodarone therapy? SATA

1. Heart rate
2. Ophthalmologic exam
3. LFTs
4. Serum uric acid level

Answer 3

Heart rate
Ophthalmologic exam
LFTs

Question 4

Nitroglycerin produces vasodilation via relaxation of smooth muscle in peripheral veins and arteries. T/F

Answer 4

True

Question 5

Digoxin has positive inotropic effects. T/F

Answer 5

True

Question 6

Amiodarone is a class 1 antiarrhythmic. T/F

Answer 6

False it is class III

Question 7

Amiodarone inhibits CYP 2C9 and 2C19. T/F

Answer 7

False it is a CYP
2C9 Inhibitor
2D6 Inhibitor
3A4 Substrate

Question 8

Due to possible arrhythmia risk, patients converted from sotalol IV to oral tablet should be admitted for monitoring with ECG and liver functions for at least 3 days. T/F

Answer 8

False

Question 9

Which of the following are safety monitoring parameters of sotalol therapy? SATA

1. QTc interval
2. Ophthalmologic exam
3. Heart rate
4. Serum uric acid level

Answer 9

QTc interval

Heart Rate

Question 10

Which of the following is NOT a serious side effect of digoxin?

1. Blurred or yellow skin discoloration
2. Confusion
3. Proarrhythmic effects
4. Hallucinations

Answer 10

Blurred or yellow skin discoloration